As the prostate specific antigen (PSA) screening test is not able to differentiate aggressive vs nonaggressive tumors, many males were diagnosed and treated for cancers that did not need intervention when PSA screening was first introduced and common in the US (approximately 1994 to 2008). This evidence concerns the gene KLK3 and cancer.